Undifferentiated-dedifferentiated endometrial carcinoma; the reappearance of an old friend with insights into the new data.
TCGA molecular classification
Undifferentiated endometrial carcinoma
dedifferentiated endometrial carcinoma
immunohistochemistry
morphology
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
09
02
2023
accepted:
21
03
2023
medline:
8
5
2023
pubmed:
26
3
2023
entrez:
25
3
2023
Statut:
ppublish
Résumé
Endometrial carcinoma is a common malignancy in women and shows increasing incidence. Except for its two main pathogenetic types I and II, the continuing evolution on molecular genetics have led to a new classification system (TCGA), that includes four main molecular subtypes: (i) POLE-mutant (ultramutated), (ii) hypermutated (MSI), (iii) copy-number low/MSS (p53wt) and (iv) copy-number high/serous-like (p53mut). The undifferentiated and dedifferentiated endometrial carcinomas are rare and clinically aggressive variants, comprising about 10% of the high-grade endometrial carcinomas and 2% of the endometrial carcinomas in general. Until recently, they were under-recognized and not fully described morphologically and immunohistochemically/molecularly. Their recognition diagnostically is crucial because of their poor prognosis; approximately 40% of patients with these subtypes will die within 0.5-20 months after diagnosis, so additional therapeutic strategies are important for an effective management. Because of their rarity, the responsiveness to other than conventional treatment, such as immunotherapy, has not been sufficiently investigated yet. The aim of this review is to provide an update on the knowledge about these two uncommon subtypes according to the current literature.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-236Informations de copyright
© 2023 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Parkash V, Matias-Guiu X, Oliva E, Malpica A, McCluggage WG. Current practices in the processing, diagnosis, and reporting of endometrial carcinoma: results of a web-based survey by the International Society of Gynecological Pathologists (ISGyP). Int J Gynecol Pathol. 2019;38(1):S3-8.
Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316-21.
Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol. 2006;25(1):52-8. Erratum in: Int J Gynecol Pathol. 2006;25(3):304. PMID: 16306785.
Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology. 2007;39(1):134-8.
Silverberg SG, Nogales F. Tumours of the uterine corpus. In: Tavassoli FA, Devilee P, editors. Pathology and genetics: Tumours of the Breast and Female Genital Organs. Volume 4. Lyon: IARC Press, 2003: 217-57.
Zaino R, Carinelli SG, Eng C. Tumours of the uterine corpus. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC Press, 2014: 121-54.
Tumours of the uterine corpus. Female Genital Tumours, WHO Classification of Tumours. 5th ed. Lyon: Internal Agency for Research on Cancer (IARC). 2020.
Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: morphologic and Immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019;38:S40-63. https://doi.org/10.1097/PGP.0000000000000491
PathologyOutlines.com. Uterus, undifferentiated/dedifferentiated carcinoma, 2020-2022 (minor changes: 17 Dec 2021).
Blaustein's Pathology of the Female Genital Tract. 7th ed. Cham: Springer Nature Switzerland AG. 2019: 514-6.
Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23(6):781-9.
Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009;33(12):1869-77.
Al-Loh S, Al-Hussaini M. Undifferentiated endometrial carcinoma: a diagnosis frequently overlooked. Arch Pathol Lab Med. 2013;137(3):438-42.
Al-Hussaini M, Lataifeh I, Jaradat I, Abdeen G, Otay L, Badran O, et al. Undifferentiated endometrial carcinoma, an Immunohistochemical study including PD-L1 testing of a series of cases from a single cancer center. Int J Gynecol Pathol. 2018;37(6):564-74.
Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol. 2016;29(Suppl 1):S29-44.
Vroobel KM, Attygalle AD. Sarcomatous transformation in undifferentiated/dedifferentiated endometrial carcinoma: an Underrecognized phenomenon and diagnostic pitfall. Int J Gynecol Pathol. 2020;39(5):485-92.
Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E, Santón A, López-García MÁ, Muñoz G, et al. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Mod Pathol. 2016;29(11):1390-8. https://doi.org/10.1038/modpathol.2016.132 Erratum in: Mod Pathol. 2016;29(12):1594. PMID: 27491810; PMCID: PMC5708881.
Ramalingam P, Masand RP, Euscher ED, Malpica A. Undifferentiated carcinoma of the endometrium: an expanded Immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. Int J Gynecol Pathol. 2016;35(5):410-8. https://doi.org/10.1097/PGP.0000000000000248
Busca A, Parra-Herran C, Nofech-Mozes S, Djordjevic B, Ismiil N, Cesari M, et al. Undifferentiated endometrial carcinoma arising in the background of high-grade endometrial carcinoma - Expanding the definition of dedifferentiated endometrial carcinoma, 2020. https://doi.org/10.1111/his.14186
McCluggage WG. Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings. J Clin Pathol. 2012;65(4):293-301.
Karnezis AN, Hoang LN, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016;29(3):302-14.
Tessier-Cloutier B, Coatham M, Carey M, Nelson GS, Hamilton S, Lum A, et al. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma. J Pathol Clin Res. 2021;7(2):144-53.
Ono R, Nakayama K, Nakamura K, et al. Dedifferentiated endometrial carcinoma could be a target for immune checkpoint inhibitors (anti PD-1/PD-L1 antibodies). Int J Mol Sci. 2019;20(15):3744.
Hoang LN, Lee YS, Karnezis AN, Tessier-Cloutier B, Almandani N, Coatham M, et al. Immunophenotypic features of dedifferentiated endometrial carcinoma insights from BRG1/INI1-deficient tumors. Histopath. 2016;69(4):560-9. https://doi.org/10.1111//his.12989
Ramalingam P, Croce S, McCluggage WG. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology. 2017;70(3):359-66. https://doi.org/10.1111/his.13091
Amarin Z, Mansour R, Al-Ghnimat S, Al-Hussaini M. Differential characteristics and prognosis of PD-L1-positive endometrial carcinomas: a retrospective chart review. Life. 2021;11:1047. https://doi.org/10.3390/life11101047
Travaglino A, Raffone A, Gencarelli A, Saracinelli S, Riccardi C, Mollo A, et al. Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: a systematic review and meta-analysis. Gynecol Oncol. 2021;160(2):579-85. https://doi.org/10.1016/j.ygyno.2020.11.015
The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. https://doi.org/10.1038/nature12113 Erratum in: Nature 2013;500(7461):242.
Carlson J, McCluggage WG. Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Curr Opin Oncol. 2019;31(5):411-9. https://doi.org/10.1097/CCO.0000000000000560
Santoro A, Angelico G, Travaglino A, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers (Basel). 2021;13(11):2623. https://doi.org/10.3390/cancers13112623
Travaglino A, Raffone A, Mascolo M, Guida M, Insabato L, Zannoni GF, et al. TCGA molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma. Pathol Oncol Res. 2020;26(3):1411-6. https://doi.org/10.1007/s12253-019-00784-0
Köbel M, Hoang LN, Tessier-Cloutier B, Meng B, Soslow RA, Stewart CJR, et al. Undifferentiated endometrial carcinomas show frequent loss of Core switch/sucrose nonfermentable complex proteins. Am J Surg Pathol. 2018;42(1):76-83. https://doi.org/10.1097/PAS.0000000000000941
Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J. Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Am J Surg Pathol. 2017 Aug;41(8):1121-8. https://doi.org/10.1097/PAS.0000000000000873
Zhang K, Liu Y, Liu X, Du J, Wang Y, Yang J, et al. Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas. Pathology. 2021;53(2):179-86. https://doi.org/10.1016/j.pathol.2020.07.015
Santoro A, Angelico G, Travaglino A, Raffone A, Arciuolo D, D'Alessandris N, et al. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: a possible prognostic risk stratification. Gynecol Oncol. 2021;161(2):629-35. https://doi.org/10.1016/j.ygyno.2021.02.029
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. https://doi.org/10.1136/ijgc-2020-002230
Travaglino A, Raffone A, Stradella C, Esposito R, Moretta P, Gallo C, et al. Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet. 2020;301(6):1355-63. https://doi.org/10.1007/s00404-020-05542-1
AlHilli M, Elson P, Rybicki L, Amarnath S, Yang B, Michener CM, et al. Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. Int J Gynecol Cancer. 2019;29(7):1126-33. https://doi.org/10.1136/ijgc-2019-000465
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, et al. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. Int J Mol Sci. 2022;23(19):11684. https://doi.org/10.3390/ijms231911684